Investment Rating - The report maintains a Neutral rating for the company [3][7]. Core Views - The company is expected to achieve a revenue growth of 13% in 2025, driven primarily by the continued ramp-up of innovative drug sales and normalized contributions from licensing income [2][7]. - The target price is set at HKD 69.50, indicating a potential upside of 5.3% from the current price of HKD 66.00 [1][7]. Financial Performance Summary - Revenue projections for 2026 are estimated at RMB 35,377 million, a slight decrease of 0.6% from previous forecasts [6]. - Gross profit is expected to be RMB 30,707 million, with a gross margin of 86.8% [6][14]. - Net profit attributable to shareholders is projected at RMB 8,887 million, reflecting a net margin of 25.1% [6][14]. - The company has a strong pipeline with 24 first-class new drugs and 5 second-class new drugs approved for sale in mainland China, with expectations for 53 new products/indications to be approved from 2026 to 2028 [7]. Growth Drivers - Innovative drugs are projected to contribute 58% of total revenue by 2025, with significant growth expected from new products such as 瑞维鲁胺, 达尔西利, and 恒格列净 [2][7]. - The company anticipates a 30% year-on-year growth in innovative drug sales in 2026, supported by new products entering the national medical insurance [7]. - Licensing income is expected to reach RMB 3.39 billion in 2025, with further contributions from collaborations, including a projected USD 250 million from GSK [7]. Valuation Metrics - The company's current valuation is considered reasonable, with target prices reflecting a potential upside of 5% in the Hong Kong market and 14% in the A-share market [2][7]. - The DCF valuation model indicates a per-share value of RMB 63.18 or HKD 69.50 [8].
恒瑞医药（01276）：2025年创新药贡献58%收入，新品放量+国际化共驱高增长，维持中性